晚期癌症患者接受免疫检查点抑制剂后发生皮肤免疫相关不良事件与更长总生存期相关:一项多机构队列研究
研究纳入Mass General Brigham医疗系统和Dana-Farber癌症研究所的3731例免疫检查点抑制剂(ICI)接受者,18.1%发生皮肤免疫相关不良事件(cirAE)。多变量时变Cox模型显示cirAE与死亡风险降低相关(HR=0.87,P=.027),黑色素瘤患者中更明显(HR=0.67,P=.003)。
要点
- 3731例ICI接受者中18.1%发生cirAE,cirAE与死亡风险降低相关(HR=0.87,P=.027)。
- 黑色素瘤患者中cirAE与更好生存相关(HR=0.67,P=.003)。
- 苔藓样疹、银屑病样疹、白癜风、孤立性瘙痒、痤疮样疹和非特异性皮疹均与更好生存显著相关。
核心结论
- cirAE的发生与ICI接受者生存改善相关,尤其是黑色素瘤患者。
研究设计与样本
- 多机构队列研究,从Mass General Brigham医疗系统和Dana-Farber癌症研究所识别ICI接受者,共3731例。
- 回顾患者病历以确定ICI开始后2年内cirAE的发生情况。
- 采用多变量时变Cox比例风险模型,调整年龄、性别、种族/族裔、Charlson合并症指数、ICI类型、癌症类型和ICI开始年份。
主要发现
- 3731例ICI接受者中18.1%发生cirAE。
- 6个月地标分析和时变Cox模型显示,发生cirAE的患者与死亡风险降低相关(HR=0.87,P=.027)。
- 黑色素瘤患者中,cirAE与死亡风险降低相关(HR=0.67,P=.003)。
- 苔藓样疹(HR=0.51,P<.001)、银屑病样疹(HR=0.52,P=.005)、白癜风(HR=0.29,P=.007)、无可见皮疹的孤立性瘙痒(HR=0.71,P=.007)、痤疮样疹(HR=0.34,P=.025)和非特异性皮疹(HR=0.68,P<.001)经多重比较调整后均与更好生存显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 回顾性设计。
- 单一地理区域。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cutaneous immune-related adverse events (cirAEs) occur in up to 40% of immune checkpoint inhibitor (ICI) recipients. However, the association of cirAEs with survival remains unclear. OBJECTIVE: To investigate the association of cirAEs with survival among ICI recipients. METHODS: ICI recipients were identified from the Mass General Brigham healthcare system and Dana-Farber Cancer Institute. Patient charts were reviewed for cirAE development within 2 years after ICI initiation. Multivariate time-varying Cox proportional hazards models, adjusted for age, sex, race/ethnicity, Charlson Comorbidity Index, ICI type, cancer type, and year of ICI initiation were utilized to investigate the impact of cirAE development on overall survival. RESULTS: Of the 3731 ICI recipients, 18.1% developed a cirAE. Six-month landmark analysis and time-varying Cox proportional hazards models demonstrated that patients who developed cirAEs were associated with decreased mortality (hazardratio [HR] = 0.87, P = .027), particularly in patients with melanoma (HR = 0.67, P = .003). Among individual morphologies, lichenoid eruption (HR = 0.51, P < .001), psoriasiform eruption (HR = 0.52, P = .005), vitiligo (HR = 0.29, P = .007), isolated pruritus without visible manifestation of rash (HR = 0.71, P = .007), acneiform eruption (HR = 0.34, P = .025), and non-specific rash (HR = 0.68, P < .001) were significantly associated with better survival after multiple comparisons adjustment. LIMITATIONS: Retrospective design; single geography. CONCLUSION: CirAE development is associated with improved survival among ICI recipients, especially patients with melanoma.
引用
- Zhang S, Tang K, Wan G, et al. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study. J Am Acad Dermatol. 2023. PMID: 36736626. doi:10.1016/j.jaad.2022.12.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。